NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that it has been invited to be one of twenty Israeli life science companies constituting the Israeli delegation to the 2009 BIO International Convention, to be held on May 18-21 in Atlanta. Mr. Zami Aberman, President and CEO, and Dr. William Prather, Sr. VP Corporate Development, will be available at the Israel Pavilion, Booth: 3747 on the Exhibition Floor, to address Pluristem’s upcoming clinical trial in the US, following FDA clearance, as well as the Company’s adult stem cell product pipeline.
